These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Nikoo M; Radnia H; Farokhnia M; Mohammadi MR; Akhondzadeh S Clin Neuropharmacol; 2015; 38(1):11-7. PubMed ID: 25580916 [TBL] [Abstract][Full Text] [Related]
45. Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. Brunet A; Saumier D; Liu A; Streiner DL; Tremblay J; Pitman RK Am J Psychiatry; 2018 May; 175(5):427-433. PubMed ID: 29325446 [TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Tucker P; Trautman RP; Wyatt DB; Thompson J; Wu SC; Capece JA; Rosenthal NR J Clin Psychiatry; 2007 Feb; 68(2):201-6. PubMed ID: 17335317 [TBL] [Abstract][Full Text] [Related]
54. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Ramakrishnan N; Lijffijt M; Green CE; Balderston NL; Murphy N; Grillon C; Iqbal T; Vo-Le B; O'Brien B; Murrough JW; Swann AC; Mathew SJ Depress Anxiety; 2021 Nov; 38(11):1108-1119. PubMed ID: 34254405 [TBL] [Abstract][Full Text] [Related]
55. A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. Arancini L; Mohebbi M; Berk M; Dean OM; Bortolasci CC; Spolding B; Zazula R; Dodd S Eur Neuropsychopharmacol; 2021 Dec; 53():120-126. PubMed ID: 34757312 [TBL] [Abstract][Full Text] [Related]
57. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. Rauch SAM; Kim HM; Powell C; Tuerk PW; Simon NM; Acierno R; Allard CB; Norman SB; Venners MR; Rothbaum BO; Stein MB; Porter K; Martis B; King AP; Liberzon I; Phan KL; Hoge CW JAMA Psychiatry; 2019 Feb; 76(2):117-126. PubMed ID: 30516797 [TBL] [Abstract][Full Text] [Related]
58. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567 [TBL] [Abstract][Full Text] [Related]
60. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]